Boston Scientific stock gets new lead independent director
Published on 11/18/2026 at 13:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey governance changes
- David S. Wichmann will become Boston Scientific's Lead Independent Director on January 1, 2027.
- The board approved incentive plans linked to global sales, adjusted earnings per share, relative shareholder returns and organic net sales growth.
- Edward J. Ludwig will remain on the board after leaving the lead independent role.
Boston Scientific's board appointed David S. Wichmann as Lead Independent Director on November 17, 2026, according to the company's Form 8-K filing. The appointment takes effect on January 1, 2027.
Wichmann will succeed Edward J. Ludwig, who has held the lead independent role since 2016 and will remain a member of the board. Wichmann has served as a Boston Scientific director since 2021. He is also chair of the Audit Committee and a member of the Risk, Science and Technology Committee.
Incentives tied to operating goals
The same filing said the board approved the 2027 Annual Bonus Plan and two performance-share programs. The cash plan covers the January 1 to December 31, 2027 performance year and links company performance to global sales and adjusted earnings per share. The board retains discretion to reduce the payout percentage based on quality objectives and the performance of the company's quality systems.
Individual awards under the cash plan can range from zero to 225% of target. The board also approved a relative total shareholder return program and an organic net sales growth program covering January 1, 2027 through December 31, 2029. Each program provides for awards ranging from zero to 200% of target, subject to performance and payment conditions.
The relative return plan compares Boston Scientific with companies in the S&P 500 Healthcare Index. The organic growth plan measures performance against the company's financial plan and excludes foreign-exchange effects and certain acquisitions and divestitures that lack a full period of comparable sales.
Governance context for investors
The leadership change is a board-level succession rather than a change in Boston Scientific's chief executive or operating management. Ludwig's continued board service preserves his experience while Wichmann takes on the lead independent role at the start of the new calendar year.
The incentive structure places sales growth, adjusted earnings per share, quality and longer-term shareholder returns at the center of executive compensation. For investors, those measures offer a framework for assessing how the company aligns management rewards with operating execution, although the filing does not change the company's previously reported financial outlook.
Boston Scientific stock traded at 39.18 euros on Lang & Schwarz at 13:05 CET on Wednesday, November 18.
Boston Scientific Corporation
- ISIN: US1011371077
- Ticker: BSX
- Primary exchange: New York Stock Exchange
- Latest quote: 39.18 euros on Lang & Schwarz, Wednesday, November 18, 2026, 13:05 CET
- Sector: Healthcare
- Industry: Medical devices
The S&P 500 remains the relevant broad US equity benchmark for the company's home market.
